

## POLYMERS

The present invention relates to polymers useful as therapeutic and diagnostic agents and to processes for their preparation. In particular, the invention relates to amino acid based biodegradable polymers for use in targeting of diagnostic imaging and therapeutic agents.

The polymers in accordance with the invention are suitable for use in a variety of applications where specific delivery is desirable, and are particularly suited for the delivery of biologically active agents. However, a preferred use of the polymers of the invention is in the enhancement of images of selected mammalian organs, tissues and cells *in vivo* using MR, X-ray, ultrasound, light and nuclear imaging techniques by virtue of their enhanced imaging properties and site specificity. The polymers are especially suited for use as intravascular contrast agents and blood pool agents in such imaging techniques. As such they may be used in imaging blood vessels, e.g. in magnetic resonance angiography, in the measurement of blood flow and volume, in the identification and characterization of lesions by virtue of differences in vascularity from normal tissue, in the imaging of the lungs for the evaluation of pulmonary disease and in blood perfusion studies.

Medical imaging techniques, such as MRI and X-ray, have become extremely important tools in the diagnosis and treatment of disease. Some imaging of internal parts relies on inherent attributes of those parts, such as bones, to be differentiated from surrounding tissue in a particular type of imaging, such as X-ray. Other organs and anatomical components are only visible when specifically highlighted by particular imaging techniques.

One such technique with the potential to provide

images of a wide variety of anatomical components involves biotargeting image-enhancing metals. Such a procedure has the possibility of creating or enhancing images of specific organs and/or tumors or other such localized sites within the body, while reducing the background and potential interference created by simultaneous highlighting of non-desired sites.

It has been recognized for many years that chelating various metals increases the physiologically tolerable dosage of such metals and so permits their use *in vivo* to enhance images of body parts. One chelate complex which has been the subject of much study is Gd-DTPA. However, despite its satisfactory relaxivity and safety, this has several disadvantages. Due to its low molecular weight, Gd-DTPA is rapidly cleared from the blood stream. This severely limits the imaging window, the number of optimal images that can be taken after each injection, and increases the agent's required dose and relative toxicity. Moreover, such simple metal chelate image enhancers, without further modification, do not generally provide any significant site specificity.

The attachment of metal chelates to tissue or organ targeting molecules, e.g. biomolecules such as proteins, in order to produce site specific therapeutic or diagnostic agents has been widely suggested. Many such bifunctional chelating agents, i.e. agents which by virtue of the chelant moiety are capable of strongly binding a therapeutically or diagnostically useful metal ion and by virtue of the site-specific molecular component are capable of selective delivery of the chelated metal ion to the body site of interest, are known or have been proposed. However, drawbacks of conjugating metal chelates to protein carriers for use in MR imaging include inappropriate biodistribution, toxicity and short blood half-life. Their use in MR imaging is therefore limited. In addition, proteins

provide a defined structure not subject to wide synthetic variation.

Site-specific uses of various imaging techniques are enhanced by the use of a multiplicity of the appropriate metal ion conjugated to a site-directed macromolecule and numerous attempts have been made to produce bifunctional polychelants with increased numbers of chelant moieties per site-specific macromolecule.

For site-specific image enhancement however it is important that the site specificity of the tissue or organ targeting moiety of such chelates of bifunctional chelants should not be destroyed by the conjugation to the targeting moiety of the chelant moiety. Where the bifunctional chelant contains only one chelant moiety this is not generally a severe problem. However, when attempts have been made to produce bifunctional polychelants by conjugating several chelant moieties onto a single site-specific macromolecule, it has been found not only may the maximum achievable chelant:site-specific macromolecule ratio be relatively limited but as the ratio achieved increases, so the site-specificity of the resulting bifunctional polychelant decreases.

In order to overcome the problems of attaching larger numbers of chelant moieties to a site-specific macromolecule without destroying its site-specificity, i.e. without disturbing its binding site(s), there have been many proposals for the use of a backbone molecule to which large numbers of chelant moieties can be attached to produce a polychelant, one or more of which can then be conjugated to the site-specific macromolecule to produce the bifunctional polychelant.

Bifunctional polychelants in which the chelant moieties are residues of open chain PAPCAs, such as EDTA and DTPA, and in which the backbone molecule is a polyamine such as polylysine or polyethyleneimine have been produced.

WO-A-90/12050 describes techniques for producing

- 4 -

polychelants comprising macrocyclic chelating moieties, such as polylysine-polyDOTA, and for the preparation of corresponding bifunctional polychelants. This document also suggests the use of starburst dendrimers, such as a sixth generation PAMAM starburst dendrimer as the skeleton for such polychelants. WO-A-93/06868 similarly describes polychelants comprising dendrimeric backbone molecules linked to a plurality of macrocyclic chelant moieties, e.g. DOTA residues. These in turn may be conjugated to a site-directed molecule, e.g. a protein. However, to date starburst dendrimers have found little use in imaging.

Thus, there still exists a need for other polymeric contrast agents, e.g. MR, X-ray, ultrasound, light-based and nuclear, which contain relatively large amounts of metal per molecule, are of a molecular weight which enables them to be circulated within the blood for extended periods of time and which exhibit improved biodistribution.

The present invention lies in the recognition that co-polymers of amino acids carrying or attached to one or more reporter groups, e.g. chelating moieties, fluors, or absorbers, are particularly suitable for diagnostic and therapeutic use by virtue both of their structures and of their substantial uniformity in terms of molecular weight distribution. Moreover, by virtue of their relatively high molecular weights such compounds can function as effective blood pool agents without requiring attachment to site-directed biomolecules.

Thus viewed from one aspect the invention provides a compound comprising a linear, branched or dendrimeric polymer backbone with linked thereto at least one reporter moiety, said polymer backbone comprising a plurality of amine-containing acids, e.g. amino acid residues or similar non-native amine-containing acids; with the proviso that when the polymer backbone is

0052  
0053  
0054  
0055  
0056  
0057  
0058  
0059  
0060  
0061  
0062  
0063  
0064  
0065  
0066  
0067  
0068  
0069  
0070  
0071  
0072  
0073  
0074  
0075  
0076  
0077  
0078  
0079  
0080  
0081  
0082  
0083  
0084  
0085  
0086  
0087  
0088  
0089  
0090  
0091  
0092  
0093  
0094  
0095  
0096  
0097  
0098  
0099  
0100  
0101  
0102  
0103  
0104  
0105  
0106  
0107  
0108  
0109  
0110  
0111  
0112  
0113  
0114  
0115  
0116  
0117  
0118  
0119  
0120  
0121  
0122  
0123  
0124  
0125  
0126  
0127  
0128  
0129  
0130  
0131  
0132  
0133  
0134  
0135  
0136  
0137  
0138  
0139  
0140  
0141  
0142  
0143  
0144  
0145  
0146  
0147  
0148  
0149  
0150  
0151  
0152  
0153  
0154  
0155  
0156  
0157  
0158  
0159  
0160  
0161  
0162  
0163  
0164  
0165  
0166  
0167  
0168  
0169  
0170  
0171  
0172  
0173  
0174  
0175  
0176  
0177  
0178  
0179  
0180  
0181  
0182  
0183  
0184  
0185  
0186  
0187  
0188  
0189  
0190  
0191  
0192  
0193  
0194  
0195  
0196  
0197  
0198  
0199  
0200  
0201  
0202  
0203  
0204  
0205  
0206  
0207  
0208  
0209  
0210  
0211  
0212  
0213  
0214  
0215  
0216  
0217  
0218  
0219  
0220  
0221  
0222  
0223  
0224  
0225  
0226  
0227  
0228  
0229  
0230  
0231  
0232  
0233  
0234  
0235  
0236  
0237  
0238  
0239  
0240  
0241  
0242  
0243  
0244  
0245  
0246  
0247  
0248  
0249  
0250  
0251  
0252  
0253  
0254  
0255  
0256  
0257  
0258  
0259  
0260  
0261  
0262  
0263  
0264  
0265  
0266  
0267  
0268  
0269  
0270  
0271  
0272  
0273  
0274  
0275  
0276  
0277  
0278  
0279  
0280  
0281  
0282  
0283  
0284  
0285  
0286  
0287  
0288  
0289  
0290  
0291  
0292  
0293  
0294  
0295  
0296  
0297  
0298  
0299  
0300  
0301  
0302  
0303  
0304  
0305  
0306  
0307  
0308  
0309  
0310  
0311  
0312  
0313  
0314  
0315  
0316  
0317  
0318  
0319  
0320  
0321  
0322  
0323  
0324  
0325  
0326  
0327  
0328  
0329  
0330  
0331  
0332  
0333  
0334  
0335  
0336  
0337  
0338  
0339  
0340  
0341  
0342  
0343  
0344  
0345  
0346  
0347  
0348  
0349  
0350  
0351  
0352  
0353  
0354  
0355  
0356  
0357  
0358  
0359  
0360  
0361  
0362  
0363  
0364  
0365  
0366  
0367  
0368  
0369  
0370  
0371  
0372  
0373  
0374  
0375  
0376  
0377  
0378  
0379  
0380  
0381  
0382  
0383  
0384  
0385  
0386  
0387  
0388  
0389  
0390  
0391  
0392  
0393  
0394  
0395  
0396  
0397  
0398  
0399  
0400  
0401  
0402  
0403  
0404  
0405  
0406  
0407  
0408  
0409  
0410  
0411  
0412  
0413  
0414  
0415  
0416  
0417  
0418  
0419  
0420  
0421  
0422  
0423  
0424  
0425  
0426  
0427  
0428  
0429  
0430  
0431  
0432  
0433  
0434  
0435  
0436  
0437  
0438  
0439  
0440  
0441  
0442  
0443  
0444  
0445  
0446  
0447  
0448  
0449  
0450  
0451  
0452  
0453  
0454  
0455  
0456  
0457  
0458  
0459  
0460  
0461  
0462  
0463  
0464  
0465  
0466  
0467  
0468  
0469  
0470  
0471  
0472  
0473  
0474  
0475  
0476  
0477  
0478  
0479  
0480  
0481  
0482  
0483  
0484  
0485  
0486  
0487  
0488  
0489  
0490  
0491  
0492  
0493  
0494  
0495  
0496  
0497  
0498  
0499  
0500  
0501  
0502  
0503  
0504  
0505  
0506  
0507  
0508  
0509  
0510  
0511  
0512  
0513  
0514  
0515  
0516  
0517  
0518  
0519  
0520  
0521  
0522  
0523  
0524  
0525  
0526  
0527  
0528  
0529  
0530  
0531  
0532  
0533  
0534  
0535  
0536  
0537  
0538  
0539  
0540  
0541  
0542  
0543  
0544  
0545  
0546  
0547  
0548  
0549  
0550  
0551  
0552  
0553  
0554  
0555  
0556  
0557  
0558  
0559  
0560  
0561  
0562  
0563  
0564  
0565  
0566  
0567  
0568  
0569  
0570  
0571  
0572  
0573  
0574  
0575  
0576  
0577  
0578  
0579  
0580  
0581  
0582  
0583  
0584  
0585  
0586  
0587  
0588  
0589  
0590  
0591  
0592  
0593  
0594  
0595  
0596  
0597  
0598  
0599  
0600  
0601  
0602  
0603  
0604  
0605  
0606  
0607  
0608  
0609  
0610  
0611  
0612  
0613  
0614  
0615  
0616  
0617  
0618  
0619  
0620  
0621  
0622  
0623  
0624  
0625  
0626  
0627  
0628  
0629  
0630  
0631  
0632  
0633  
0634  
0635  
0636  
0637  
0638  
0639  
0640  
0641  
0642  
0643  
0644  
0645  
0646  
0647  
0648  
0649  
0650  
0651  
0652  
0653  
0654  
0655  
0656  
0657  
0658  
0659  
0660  
0661  
0662  
0663  
0664  
0665  
0666  
0667  
0668  
0669  
0660  
0661  
0662  
0663  
0664  
0665  
0666  
0667  
0668  
0669  
0670  
0671  
0672  
0673  
0674  
0675  
0676  
0677  
0678  
0679  
0680  
0681  
0682  
0683  
0684  
0685  
0686  
0687  
0688  
0689  
0690  
0691  
0692  
0693  
0694  
0695  
0696  
0697  
0698  
0699  
0700  
0701  
0702  
0703  
0704  
0705  
0706  
0707  
0708  
0709  
07010  
07011  
07012  
07013  
07014  
07015  
07016  
07017  
07018  
07019  
07020  
07021  
07022  
07023  
07024  
07025  
07026  
07027  
07028  
07029  
07030  
07031  
07032  
07033  
07034  
07035  
07036  
07037  
07038  
07039  
07040  
07041  
07042  
07043  
07044  
07045  
07046  
07047  
07048  
07049  
07050  
07051  
07052  
07053  
07054  
07055  
07056  
07057  
07058  
07059  
07060  
07061  
07062  
07063  
07064  
07065  
07066  
07067  
07068  
07069  
07070  
07071  
07072  
07073  
07074  
07075  
07076  
07077  
07078  
07079  
07080  
07081  
07082  
07083  
07084  
07085  
07086  
07087  
07088  
07089  
07090  
07091  
07092  
07093  
07094  
07095  
07096  
07097  
07098  
07099  
070100  
070101  
070102  
070103  
070104  
070105  
070106  
070107  
070108  
070109  
070110  
070111  
070112  
070113  
070114  
070115  
070116  
070117  
070118  
070119  
070120  
070121  
070122  
070123  
070124  
070125  
070126  
070127  
070128  
070129  
070130  
070131  
070132  
070133  
070134  
070135  
070136  
070137  
070138  
070139  
070140  
070141  
070142  
070143  
070144  
070145  
070146  
070147  
070148  
070149  
070150  
070151  
070152  
070153  
070154  
070155  
070156  
070157  
070158  
070159  
070160  
070161  
070162  
070163  
070164  
070165  
070166  
070167  
070168  
070169  
070170  
070171  
070172  
070173  
070174  
070175  
070176  
070177  
070178  
070179  
070180  
070181  
070182  
070183  
070184  
070185  
070186  
070187  
070188  
070189  
070190  
070191  
070192  
070193  
070194  
070195  
070196  
070197  
070198  
070199  
070200  
070201  
070202  
070203  
070204  
070205  
070206  
070207  
070208  
070209  
070210  
070211  
070212  
070213  
070214  
070215  
070216  
070217  
070218  
070219  
070220  
070221  
070222  
070223  
070224  
070225  
070226  
070227  
070228  
070229  
070230  
070231  
070232  
070233  
070234  
070235  
070236  
070237  
070238  
070239  
070240  
070241  
070242  
070243  
070244  
070245  
070246  
070247  
070248  
070249  
070250  
070251  
070252  
070253  
070254  
070255  
070256  
070257  
070258  
070259  
070260  
070261  
070262  
070263  
070264  
070265  
070266  
070267  
070268  
070269  
070270  
070271  
070272  
070273  
070274  
070275  
070276  
070277  
070278  
070279  
070280  
070281  
070282  
070283  
070284  
070285  
070286  
070287  
070288  
070289  
070290  
070291  
070292  
070293  
070294  
070295  
070296  
070297  
070298  
070299  
070200  
070201  
070202  
070203  
070204  
070205  
070206  
070207  
070208  
070209  
070210  
070211  
070212  
070213  
070214  
070215  
070216  
070217  
070218  
070219  
070220  
070221  
070222  
070223  
070224  
070225  
070226  
070227  
070228  
070229  
070230  
070231  
070232  
070233  
070234  
070235  
070236  
070237  
070238  
070239  
070240  
070241  
070242  
070243  
070244  
070245  
070246  
070247  
070248  
070249  
070250  
070251  
070252  
070253  
070254  
070255  
070256  
070257  
070258  
070259  
070260  
070261  
070262  
070263  
070264  
070265  
070266  
070267  
070268  
070269  
070270  
070271  
070272  
070273  
070274  
070275  
070276  
070277  
070278  
070279  
070280  
070281  
070282  
070283  
070284  
070285  
070286  
070287  
070288  
070289  
070290  
070291  
070292  
070293  
070294  
070295  
070296  
070297  
070298  
070299  
070200  
070201  
070202  
070203  
070204  
070205  
070206  
070207  
070208  
070209  
070210  
070211  
070212  
070213  
070214  
070215  
070216  
070217  
070218  
070219  
070220  
070221  
070222  
070223  
070224  
070225  
070226  
070227  
070228  
070229  
070230  
070231  
070232  
070233  
070234  
070235  
070236  
070237  
070238  
070239  
070240  
070241  
070242  
070243  
070244  
070245  
070246  
070247  
070248  
070249  
070250  
070251  
070252  
070253  
070254  
070255  
070256  
070257  
070258  
070259  
070260  
070261  
070262  
070263  
070264  
070265  
070266  
070267  
070268  
070269  
070270  
070271  
070272  
070273  
070274  
070275  
070276  
070277  
070278  
070279  
070280  
070281  
070282  
070283  
070284  
070285  
070286  
070287  
070288  
070289  
070290  
070291  
070292  
070293  
070294  
070295  
070296  
070297  
070298  
070299  
070200  
070201  
070202  
070203  
070204  
070205  
070206  
070207  
070208  
070209  
070210  
070211  
070212  
070213  
070214  
070215  
070216  
070217  
070218  
070219  
070220  
070221  
070222  
070223  
070224  
070225  
070226  
070227  
070228  
070229  
070230  
070231  
070232  
070233  
070234  
070235  
070236  
070237  
070238  
070239  
070240  
070241  
070242  
070243  
070244  
070245  
070246  
070247  
070248  
070249  
070250  
070251  
070252  
070253  
070254  
070255  
070256  
070257  
070258  
070259  
070260  
070261  
070262  
070263  
070264  
070265  
070266  
070267  
070268  
070269  
070270  
070271  
070272  
070273  
070274  
070275  
070276  
070277  
070278  
070279  
070280  
070281  
070282  
070283  
070284  
070285  
070286  
070287  
070288  
070289  
070290  
070291  
070292  
070293  
070294  
070295  
070296  
070297  
070298  
070299  
070200  
070201  
070202  
070203  
070204  
070205  
070206  
070207  
070208  
070209  
070210  
070211  
070212  
070213  
070214  
070215  
070216  
070217  
070218  
070219  
070220  
070221  
070222  
070223  
070224  
070225  
070226  
070227  
070228  
070229  
070230  
070231  
070232  
070233  
070234  
070235  
070236  
070237  
070238  
070239  
070240  
070241  
070242  
070243  
070244  
070245  
070246  
070247  
070248  
070249  
070250  
070251  
070252  
070253  
070254  
070255  
070256  
070257  
070258  
070259  
070260  
070261  
070262  
070263  
070264  
070265  
070266  
070267  
070268  
070269  
070270  
070271  
070272  
070273  
070274  
070275  
070276  
070277  
070278  
070279  
070280  
070281  
070282  
070283  
070284  
070285  
070286  
070287  
070288  
070289  
070290  
070291  
070292  
070293  
070294  
070295  
070296  
070297  
070298  
070299  
070200  
070201  
070202  
070203  
070204  
070205  
070206  
070207  
070208  
070209  
070210  
070211  
070212  
070213  
070214  
070215  
070216  
070217  
070218  
070219  
070220  
070221  
070222  
070223  
070224  
070225  
070226  
070227  
070228  
070229  
070230  
070231  
070232  
070233  
070234  
070235  
070236  
070237  
070238  
070239  
070240  
070241  
070242  
070243  
070244  
070245  
070246  
070247  
070248  
070249  
070250  
070251  
070252  
070253  
070254  
070255  
070256  
070257  
070258  
070259  
070260  
070261  
070262  
070263  
070264  
070265  
070266  
070267  
070268  
070269  
070270  
070271  
070272  
070273  
070274  
070275  
070276  
070277  
070278  
070279  
070280  
070281  
070282  
070283  
070284  
070285  
070286  
070287  
070288  
070289  
070290  
070291  
070292  
070293  
070294  
070295  
070296  
070297  
070298  
070299  
070200  
070201  
070202  
070203  
070204  
070205  
070206  
070207  
070208  
070209  
070210  
070211  
070212  
070213  
070214  
070215  
070216  
070217  
070218  
070219  
070220  
070221  
070222  
070223  
070224  
070225  
070226  
070227  
070228  
070229  
070230  
070231  
070232  
070233  
070234  
070235  
070236  
070237  
070238  
070239  
070240  
070241  
070242  
070243  
070244  
070245  
070246  
070247  
070248  
070249  
070250  
070251  
070252  
070253  
070254  
070255  
070256  
070257  
070258  
070259  
070260  
070261  
07

linear, the reporter moiety comprises an iodinated contrast agent, an ultrasound contrast agent, a light-based reporter or a metal chelator other than DOTA, DTPA or similar polyaminopolycarboxylic acids. When the polymer backbone is linear, the reporter moiety preferably comprises an iodinated contrast agent or TMT.

As used herein, the term "reporter moiety" is intended to define any atom, ion or molecule which may be linked to the polymer backbone to produce an effect which is detectable by any chemical, physical or biological examination. A reporter moiety may thus be either a therapeutic or diagnostic agent, e.g. a contrast agent or pharmacologic agent. Where two or more reporter moieties are attached to a given polymer backbone, these may be identical or different. Thus, these may comprise any combination of diagnostic and/or therapeutic agents. The number of attached reporter moieties depends on the structure of the polymer backbone, in particular the degree of any branching, but generally will be in the range of from 3 to 200, preferably up to 100, e.g. up to 50.


Dendrimeric (or cascade) polymers are preferred as the backbone moiety. These are formed from monomers which act as branching sites and with each successive branching a new "generation" is formed. The dendrimeric backbone molecule preferably comprises a multiplicity of native or non-native, preferably native amino acid residues arranged to extend radially outwards from a central core moiety. These amino acid residues may be terminally bonded directly, or optionally via a linking group, to one or more reporter groups. Alternatively, these may be terminally branched by the addition of further amino acid residues. A backbone molecule wherein a central branched core has itself been terminally branched once is termed a first-generation backbone molecule. Further terminal branching of the amino acid residues of first-generation backbone

- 6 -

molecules provides second, third, fourth etc. generation backbones. With each successive round of branching, the number of attachment points available for bonding to reporter groups increases. Depending on the nature of the central core moiety, branching from this may extend radially in one or more directions, resulting in either radially asymmetrical or symmetrical dendrimers. Preferably, the dendrimer backbone molecules are radially asymmetrical.

Dendimeric polymers comprising a plurality of native or non-native, preferably native amino acid residues form a further aspect of the invention. Conveniently, these comprise from 3 to 2,00 amino acid residues, e.g. from 3 to 100 amino acid residues extending radially from a central core moiety.

Whilst the core moiety may itself comprise one or more amino acid residues, other core moieties are contemplated. Typically, the core moiety may be any molecule to which a multiplicity of successive amino acid residues may be attached and may itself comprise a reporter moiety. Suitable core moieties include  $\text{H}_2\text{NCOCH}_2\text{CH}_2\text{CONH}_2$ , and



in which  $m=0-4$ ;

$\text{Y}$  represents hydrogen or an alkyl or aryl group, e.g. a  $\text{C}_{1-6}$  alkyl group; and

$\text{X}$  represents a  $-\text{CO}_2\text{H}$ ,  $-\text{SO}_2\text{Cl}$  or  $-\text{CH}_2\text{Br}$  group, as well as modifications thereto and derivatives thereof.

In one embodiment of the invention, the dendrimer core may itself comprise a reporter moiety. Thus, in another aspect, the invention provides a compound comprising a dendimeric polymer backbone extending

- 7 -

radially from a reporter moiety, said polymer backbone comprising a plurality of amino acid residues.


Preferably, biodegradable linking groups serve to link the reporter moieties to the polymer backbone. In this way, biodegradation of the compound at the targeted site results in release of the reporter moieties, e.g. an ionic or non-ionic contrast agent at the site of interest. Examples of suitable linking groups include amide, ether, thioether, guanidyl, acetal, ketal and phosphoester groups. Linkage between the backbone and the reporter groups is preferably via an amide bond, the amide nitrogen deriving from the backbone molecule and the amide carbonyl deriving from a carboxyl or carboxyl derivative on the reporter group.

The advantage of a biodegradable polymer is that it will not accumulate at the injection site, e.g. during lymphographic procedures, or in tissues, e.g. the liver during angiographic procedures provided its degradation rate is tuned to the required imaging time.

Biodegradability of the compounds of the invention can be adjusted by selection of particular linker and peptide cluster compounds. Moreover, if desired, the biodegradability of the linkers and polymer backbones can be optimised *in vitro* using purified enzymes and/or biological fluids/tissues. The use of amino acid monomers which themselves are rapidly cleared may further aid clearance after imaging.

Preferred polymer backbones are those comprising from 3 to 200 amino acid residues, preferably from 3 to 100 amino acid residues and having a molecular weight of from 300 to 20,000 daltons. These are preferably bonded via peptide bonds, thereby ensuring the biodegradability of the polymer and subsequent elimination from the body. The polyamino acid may be a polymer of a single species or at least two different species of amino acids, or may be a block copolymer. Preferably the polyamino acid is poly-L-aspartic acid.

Particularly preferred compounds in accordance with the invention are those of formula I:



wherein n is an integer of from 1 to 100; and R represents a reporter group or a biodegradable linker-reporter adduct.

In a preferred embodiment of the invention, the reporter moieties are chelating agents. These are capable of chelating metal ions with a high level of stability, and may be metallated with the appropriate metal ion(s), e.g. to enhance images in MRI, gamma scintigraphy or X-ray or to deliver cytotoxic doses of radioactivity to kill undesirable cells such as tumors. Conveniently, the chelating agents are contrast agents comprising at least one paramagnetic metal ion. Alternatively, the chelating agents may be used in their unmetallated or undermetallated state for absorption of available metal ions *in vivo*, e.g. in metal detoxification.

The reporter moieties may also comprise therapeutic agents, e.g. antibiotic, analgesic, anti-inflammatory or other bioactive agents. Prolonged circulation in the blood of polymers carrying such agents substantially prolongs their therapeutic effect. Proteolysis of the

linking groups provides a release of therapeutic agent. Selection of a particular linking group thus provides the potential for a timed release of therapeutic agent at the desired site of interest.

If desired, the compounds in accordance with the invention can be attached by well-known methods to one or more site-directed molecules or targeting agents, e.g. a protein, to form bifunctional polymers which can enhance images and/or deliver cytotoxic doses of radioactivity to the targeted cells, tissues, organs, and/or body ducts. Targeting of contrast agents to the site of interest in this way increases the effectiveness of the imaging method. Such agents accumulate at the site of interest which is dependent upon the specificity of the targeting agent. Alternatively, the polymers may be used as blood pool agents without being coupled to site directed molecules.

For those compounds of the invention comprising a dendrimeric backbone moiety, any terminal amino acid residues may thus be bonded either directly or via a biodegradable linking group to either a reporter or a targeting agent. Preferably, where the core moiety is itself a reporter group, each terminal amino acid residue is bound via a biodegradable linking group to a targeting agent. In this way, a compound comprising more than one targeting agent can be provided. Conveniently the number of targeting agents will be from 1 to 128, preferably from 1 to 16, e.g. from 1 to 4.

In an alternative embodiment of the invention those compounds comprising a dendrimeric polymer backbone may comprise a targeting agent or site-directed macromolecule as the core moiety. The resulting peptide cluster may in turn be linked to one or more reporter moieties. Viewed from a yet further aspect, the invention thus provides a compound comprising a dendrimeric polymer backbone extending radially from a targeting agent, said polymer backbone comprising a

PCT/GB98/00270

- 10 -

plurality of amino acid residues with linked thereto at least one reporter moiety.

The heat stable STa enterotoxin from *E.coli* as described in WO-A-95/11694 is particularly suitable as a core targeting agent. Attached Figure 1 illustrates a compound of the invention in which the STa peptide is linked to a poly-l-aspartic acid cluster (Asp<sub>3</sub>) which in turn is linked to a plurality of TMT reporter molecules.

The polymers in accordance with the invention are in and of themselves useful entities in medical diagnosis and therapy, due in part to their unique localization in the body. The size of the polymer, typically 200 to 100,000 daltons, particularly 200 to 50,000 daltons, especially 10,000 to 40,000 daltons, radically alters its biodistribution. Selection of particular linking groups and/or variations in the polyamino acid sequence also affects the biodistribution of the polymers and the attached reporter or targeting agents.

The compounds of the invention generally have extended intravascular residence times, e.g. of the order of hours, although this can be specifically tailored according to the desired use of the compounds by selection of appropriate linking agents and/or modification of the polyamino acid sequence of the backbone polymer. Usually the compounds will eventually clear into the extracellular fluid (ECF) space and undergo renal excretion. Since the compounds remain primarily in the intravascular system for a diagnostically useful residence time, they are suitable for a range of uses from blood pool and cardiac perfusion imaging, CNS tumour detection and volume determination to thrombus detection and angiography. As blood pool agents they are particularly suited to use in studies of blood flow or volume, especially in relation to lesion detection and myocardial perfusion studies. The conventional monomeric MRI contrast agents which

SEARCHED  
INDEXED  
COPIED  
FILED

- 11 -

rapidly disperse into the extracellular/extravascular space cannot readily be used for these purposes. Moreover in view of their enhanced relaxivity, the polymers according to the invention can be administered at significantly reduced dosages relative to current monomeric MRI contrast agents such as GdDTPA and GdDOTA, thus providing a significantly improved safety margin in their use.

The invention thus provides compounds which are able to provide MR contrast enhancement of the blood pool for long periods of time, which have a specificity towards accumulation in various body tissues, which provide relatively large amounts of metal and whose molecular weight can be synthetically tailored to produce an agent of desired composition, molecular weight and size.

Furthermore, by suitable selection of chelated species, chelates according to the invention may be produced which are capable of functioning as X-ray agents, e.g. by choosing tungsten, and also as MR contrast agents by choosing an appropriate metal ion e.g. a lanthanide ion.

Attachment of the compounds to a site-directed molecule results in even greater *in vivo* target specificity. The site-directed molecule is preferably an antibody, antibody fragment, other protein or other macromolecule which will travel *in vivo* to that site to deliver the chelated metals. In the present invention the capacity of this site-directed macromolecule to travel and/or bind to its target is not compromised by the addition of the chelated metals. The number of chelates per molecule is sufficient to enhance the image of that particular target.

Suitable chelating agents for attachment to the polymer backbone include both linear and macrocyclic PAPCAs. Examples of suitable PAPCAs include ethylenediamine tetraacetic acid (EDTA),


SEARCHED  SERIALIZED  INDEXED

diethylenetriamine pentaacetic acid (DTPA), 1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA), 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A), 1-oxa-4,7,10-triazacyclododecanetriacetic acid (DOXA), 1,4,7-triazacyclonanonanetriacetic acid (NOTA) and 1,4,8,11-tetraazacyclotetradecanetetraacetic acid (TETA).

Other chelating agents suitable for attachment to the polymer backbone include terpyridines such as described in US-A-5367080, e.g. 4'-(3-amino-4-methoxy-phenyl)-6,6"-bis(N',N'-dicarboxymethyl-N-methylhydrazino)-2,2':6',2"-terpyridine (THT) and 4'-(3-amino-4-methoxy-phenyl)-6,6"-bis[N,N-di(carboxymethyl)aminomethyl]-2,2':6',2"-terpyridine (TMT).

Metals that can be incorporated, through chelation, include lanthanides and other metal ions, including isotopes and radioisotopes thereof, such as, for example, Mg, Ca, Sc, Ti, B, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Sr, Y, Zr, Tc, Ru, In, Hf, W, Re, Os, Pb and Bi. The choice of metal ion for chelation will depend upon the desired therapeutic or diagnostic application.

For use in X-ray contrast imaging, the reporter moiety may comprise an ionic or non-ionic iodinated monocyclic or bis-cyclic X-ray contrast agent. By mono and bis-cyclic is meant that the contrast agents contain either one or two iodinated rings. Generally, the iodinated rings will be di- or tri-iodinated, e.g. tri-iodinated aryl rings, in particular phenyl rings. Examples of iodinated contrast agents for use in accordance with the invention include iohexol, iopentol, iopamidol and iodixanol. Conveniently, one or more iodinated contrast agents may be conjugated to form an alternating co-polymer which in turn can be attached to the polymer backbone. An example of the synthesis of such a co-polymer from iodixanol is shown below:



The bifunctional agents in accordance with the invention involve coupling the compounds to a site-directed molecule. The site-directed molecules may be any of the molecules that naturally concentrate in a selected target organ, tissue, cell or group of cells, or other location in a mammalian body, *in vivo*. These

can include amino acids, oligopeptides (e.g. hexapeptides), molecular recognition units (MRU's), single chain antibodies (SCA's), proteins, non-peptide organic molecules, Fab fragments, and antibodies. Examples of site-directed molecules include polysaccharides (e.g. CCK and hexapeptides), proteins (such as lectins, asialofetuin, polyclonal IgG, blood clotting proteins (e.g. hirudin), lipoproteins and glycoproteins), hormones, growth factors, and clotting factors (such as PF4). Exemplary site-directed proteins include *E.coli* heat stable enterotoxin STa and its analogues, polymerized fibrin fragments (e.g.,  $E_1$ ), serum amyloid precursor (SAP) proteins, low density lipoprotein (LDL) precursors, serum albumin, surface proteins of intact red blood cells, receptor binding molecules such as estrogens, liver-specific proteins/polymers such as galactosyl-neoglycoalbumin (NGA) (see Vera et al. in *Radiology* 151: 191 (1984)) N-(2-hydroxy-propyl)methacrylamide (HMPA) copolymers with varying numbers of bound galactosamines (see Duncan et al., *Biochim. Biophys. Acta* 880:62 (1986)), and allyl and 6-aminohexyl glycosides (see Wong et al., *Carbo. Res.* 170:27 (1987)), and fibrinogen.

The site-directed protein can also be an antibody. The choice of antibody, particularly the antigen specificity of the antibody, will depend on the desired use of the conjugate. Monoclonal antibodies are preferred over polyclonal antibodies.

Human serum albumin (HSA) is a preferred protein for the study of the vascular system. HSA is available commercially from a number of sources including Sigma Chemical Co. Preparation of antibodies that react with a desired antigen is well known. Antibody preparations are available commercially from a variety of sources. Fibrin fragment  $E_1$  can be prepared as described by Olexa et al. in *J. Biol. Chem.* 254:4925 (1979). Preparation of LDL precursors and SAP proteins is described by de

Beer et al. in J. Immunol. Methods 50:17 (1982). The above described articles are incorporated herein by reference in their entirety.

The compounds in accordance with the invention are conveniently prepared by conjugation of a linear, branched or dendrimeric backbone comprising a plurality of amino acid residues to one or more reporter groups in a non-reactive solvent. Linkage of the reporter groups to the backbone molecule may be effected through any reactive group and standard coupling techniques are known in the art. Preferred reaction conditions, e.g. temperature, solvents etc. depend primarily on the particular reactants and can be readily determined by those skilled in the art.

Methods for metallating any chelating agents present are within the level of skill in the art. Metals can be incorporated into a chelant moiety by any one of three general methods: direct incorporation, template synthesis and/or transmetallation. Direct incorporation is preferred.

Methods for attaching the polymer backbones to antibodies and other proteins are within the level of skill in the art. Such methods are described in Pierce 1989 Handbook and General Catalog and the references cited therein, Blatter et al, Biochem., 24:1517 (1985) and Jue et al, Biochem., 17:5399 (1978).

The polymer backbone itself may be synthesised in accordance with conventional peptide synthesis techniques. Suitable methods for forming the amino acid units are described in, for example, "Synthesis of Optically Active  $\alpha$ -Amino Acids" by Robert M. Williams (Pergamon Press, 1989). In general, the reactive side chain groups present, e.g. amino, thiol and/or carboxy, will be protected during the coupling of the individual amino acids, although it is possible to leave some side chain groups unprotected, e.g. hydroxy, primary amide groups, during the entire synthetic procedure.

The final step in the synthesis of a compound in accordance with the invention will be the deprotection of a fully protected or partly protected derivative of such a compound and such a process forms part of the invention. Thus, the present invention provides a process for producing a compound as hereinbefore described, said process comprising deprotecting a partially or fully protected derivative thereof.

In building up the peptide chain, it is in principle possible to start either at the C-terminal or the N-terminal. However, only the C-terminal starting procedure is in common use. This is due to difficulties encountered when synthesising in the N to C direction which include an unacceptably high degree of racemisation (see Konig & Geiger, *Chemische Berichte* 103:2024-2033, 1970).

Contrary to expectation, it has been found that the peptide compounds for use in accordance with the invention may be produced in good yield and high purity (< 0.1% racemisation per step) by synthesising in the amino to carboxy direction. This method of synthesis has been found to be particularly effective in preparing the dendimeric polymer backbones. In particular, these have been found to be more stable than those dendrimers derived from the more conventional Michael addition chemistry. Moreover, synthesising the polymer backbones in the amino to carboxy direction has been found to produce discrete polymers which are substantially non cross-linked and which have particularly low levels of racemic impurities.

Thus, in another aspect the invention further provides a process for the preparation of a compound comprising a linear, branched or dendimeric polymer backbone with linked thereto at least one reporter moiety, said polymer backbone comprising a plurality of amino acid residues, said process comprising:

- 17 -

- (a) stepwise linking of successive protected amino acid residues in the amino to carboxy direction to form a polymer backbone;
- (b) linking the polymer backbone to one or more reporter moieties, optionally via a linking group; and
- (c) deprotecting any protected group.

Thus, one can start at the N-terminal by reaction of a suitably protected derivative of, for example, aspartic acid with a suitably protected derivative of a second aspartic acid molecule. The first aspartic acid derivative will have a protected amino group and a free carboxyl group while the other reactant will have either a free or activated  $\alpha$ -amino group and a protected carboxyl group. After coupling, the intermediate may be purified, e.g. by chromatography, and then selectively deprotected to permit addition of further amino acid residues. This procedure is continued until the required amino acid sequence is completed.

A wide range of protecting groups for amino acids are known. Suitable amine protecting groups include carbobenzoxy (Z- or Cbz), t-butoxycarbonyl (Boc-) and 9-fluorenylmethoxycarbonyl (Fmoc-). Carboxyl protecting groups which may be used include benzyl (-Bzl) and t-butyl (-tBu).

A wide range of procedures exist for removing amine- and carboxyl-protecting groups. Amine protecting groups such as Boc and carboxyl protecting groups such as -tBu may be removed simultaneously by acid treatment, e.g. with trifluoroacetic acid.

The coupling of free amino and carboxyl groups may, for example, be effected using N,N'-dicyclohexyl carbodiimide (DCC). Other coupling agents which may be used include 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 2-(11-H-benzotriazolyl-1-yl)-

1,1,3-tetramethyluranium tetrafluoroborate (TBTU).

The coupling reactions may be effected at ambient temperatures, conveniently in a suitable solvent system, e.g. tetrahydrofuran, dimethylformamide, dimethylsulphoxide or a mixture of these solvents.

It may be convenient to carry out the peptide synthesis on a solid phase resin support. Amino acids are added stepwise to a growing peptide chain linked to an insoluble matrix, such as polystyrene beads. One advantage of this solid-phase method is that the desired product at each stage is bound to beads which can be rapidly filtered and washed so the need to purify intermediates is obviated. A number of suitable solid phase supports are known in the art, e.g. 4-hydroxy benzyl alcohol resin which has been modified to form an ester with succinic anhydride.

The compounds of the invention, especially the bifunctional polymers, may be administered to patients for imaging in amounts sufficient to yield the desired contrast with the particular imaging technique.

Generally dosages of from 0.001 to 5.0 mmoles of chelated imaging metal ion per kilogram of patient bodyweight are effective to achieve adequate contrast enhancements. For most MRI applications preferred dosages of imaging metal ion will be in the range of from 0.02 to 1.2 mmoles/kg bodyweight while for X-ray applications dosages of from 0.5 to 1.5 mmoles/kg are generally effective to achieve X-ray attenuation. Preferred dosages for most X-ray applications are from 0.8 to 1.2 mmoles of the lanthanide or heavy metal/kg bodyweight.

The dosage of the compounds of the invention for therapeutic use will depend upon the condition being treated, but in general will be of the order of from 1 pmol/kg to 1 mmol/kg bodyweight.

The compounds of the present invention may be formulated with conventional pharmaceutical or

veterinary aids, for example emulsifiers, fatty acid esters, gelling agents, stabilizers, antioxidants, osmolality adjusting agents, buffers, pH adjusting agents, etc., and may be in a form suitable for parenteral or enteral administration, for example injection or infusion or administration directly into a body cavity having an external escape duct, for example the gastrointestinal tract, the bladder or the uterus. Thus the compounds of the present invention may be in conventional pharmaceutical administration forms such as tablets, capsules, powders, solutions, suspensions, dispersions, syrups, suppositories etc. However, solutions, suspensions and dispersions in physiologically acceptable carrier media, for example water for injections, will generally be preferred.

The compounds according to the invention may therefore be formulated for administration using physiologically acceptable carriers or excipients in a manner fully within the skill of the art. For example, the compounds, optionally with the addition of pharmaceutically acceptable excipients, may be suspended or dissolved in an aqueous medium, with the resulting solution or suspension then being sterilized.

For MRI and for X-ray imaging of some portions of the body the most preferred mode for administering metal chelates as contrast agents is parenteral, e.g., intravenous administration. Parenterally administrable forms, e.g. intravenous solutions, should be sterile and free from physiologically unacceptable agents, and should have low osmolality to minimize irritation or other adverse effects upon administration, and thus the contrast medium should preferably be isotonic or slightly hypertonic. Suitable vehicles include aqueous vehicles customarily used for administering parenteral solutions such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection and

other solutions such as are described in Remington's Pharmaceutical Sciences, 15th ed., Easton: Mack Publishing Co., pp. 1405-1412 and 1461-1487 (1975) and The National Formulary XIV, 14th ed. Washington: American Pharmaceutical Association (1975). The solutions can contain preservatives, antimicrobial agents, buffers and antioxidants conventionally used for parenteral solutions, excipients and other additives which are compatible with the chelates and which will not interfere with the manufacture, storage or use of products.

Viewed from a further aspect the invention provides a pharmaceutical composition, e.g. an image enhancing or therapeutic composition, comprising a compound of the invention together with at least one pharmaceutical carrier or excipient.

Viewed from a still further aspect the invention provides the use of a compound according to the invention or a chelate thereof for the manufacture of an image enhancing contrast medium or a therapeutic composition.

Viewed from another aspect the invention provides a method of generating an image of a human or non-human animal, especially mammalian, body which method comprises administering to said body an image enhancing amount of a compound according to the invention and thereafter generating an image e.g. an MR, X-ray, ultrasound or scintigraphic image, of at least a part of said body.

The present invention will now be further illustrated by way of the following non-limiting examples. Unless otherwise indicated, all percentages given are by weight.

- 21 -

Example 1: Asymmetric peptide cluster

Z- [Asp( $\alpha$ , $\gamma$ -Asp<sub>2</sub>( $\alpha$ , $\gamma$ -Asp<sub>4</sub>( $\alpha$ , $\gamma$ -Asp<sub>6</sub>( $\alpha$ , $\gamma$ -Lys<sub>16</sub> ( $\alpha$ -Reporter<sub>16</sub>)]

(a) Bis- $\alpha$ , $\gamma$ - ( $\alpha$ , $\gamma$ - (tButyl) -Aspartyl) -N-Cbz-Aspartamide  
"Asp3 Cluster" (Compound I)

Into a 500 mL round bottom flask was added 8.5 mmoles N-Cbz-L-Aspartic acid, 10.2 mmoles N-hydroxybenzotriazole, 25 mL THF:DMF (2:1, v/v), and 10.2 mmoles EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide). After stirring at room temperature for 45 minutes, 20.4 mmoles of  $\alpha$ , $\gamma$ - (tButyl) -L-Aspartic acid and 25 mmoles of N,N'-diisopropylethylamine were added with stirring. After 4 hours, an additional 10.2 mmoles EDC was added and the reaction continued as above for 3 days. This slurry was worked up by aqueous extraction.

Purity: single spot on TLC, identity confirmed by MS and NMR. Yield: 44.5%.

(b) N-Cbz-Aspartamide- (( $\alpha$ , $\gamma$ -Aspartyl- ( $\alpha$ , $\gamma$ - (tButyl) -Aspartyl)) "Asp7 Cluster" (Compound II)

Into a 500 mL round bottom flask was added 10 mmoles Compound I, 95 mL chloroform:THF:acetonitrile (2.5:7:7), 36.4 mmoles N-hydroxybenzotriazole, and 36.5 mmoles DCC (N,N'-dicyclohexylcarbodiimide). After stirring at room temperature for 20 minutes, 40 mmoles of  $\alpha$ , $\gamma$ - (tButyl) -L-Aspartic acid was added and N,N'-diisopropylethylamine was added until the pH was approximately 7. After stirring at room temperature for 16 hours, the reaction was worked up by aqueous extraction.

Purity: single spot on TLC, identity confirmed by MS and NMR. Yield: 12.1%.

- 22 -

(c) N-Cbz-Aspartamide-(( $\alpha$ , $\gamma$ -Aspartyl- $(\alpha$ , $\gamma$ -(tButyl)-Aspartyl))) "Asp15 Cluster" (Compound III)

Step 1:

0.85 mmoles of Compound II was stirred in 200 mL of 95% trifluoroacetic acid (aq.) at room temperature for 8 hours. The reaction was evaporated to dryness at 40°C *in vacuo* and then re-evaporated to dryness from 200 mL of toluene and then from THF.

Step 2:

Into a 250 mL round bottom flask was added 0.85 mmoles from Step 1 above, 90 mL DMF:THF (1:1, v/v), 8.12 mmoles N-hydroxybenzotriazole, and 8.12 mmoles EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide). After stirring at room temperature for 20 minutes, 16.24 mmoles of  $\alpha$ , $\gamma$ -(tButyl)-L-Aspartic acid and 19.92 mmoles N,N'-diisopropylethylamine were added. After stirring at room temperature for 16 hours, the reaction was worked up by aqueous extraction and ion exchange chromatography.

Purity: single spot on TLC, identity confirmed by MS and NMR. Yield: 82.2%.

(d) N-Cbz-Aspartamide-(( $\alpha$ , $\gamma$ -Aspartyl- $(\alpha$ , $\gamma$ -Aspartyl-Aspartyl( $\alpha$ , $\gamma$ -Lysyl( $\alpha$ -methoxyethylamide,  $\epsilon$ -amine)))) "Asp15Lys16 Cluster" (Compound IV)

Step 1:

0.7 mmoles of Compound III was stirred in 200 mL of 95% trifluoroacetic acid (aq.) at room temperature for 8 hours. The reaction was evaporated to dryness at 40°C *in vacuo* and then re-evaporated to dryness from 200 mL

of toluene and then from THF.

Step 2:

Into a 250 mL round bottom flask was added 0.7 mmoles of compound from Step 1 above, 90 mL DMF:THF (1:1, v/v), 8.12 mmoles N-hydroxybenzotriazole, and 8.12 mmoles EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide). After stirring at room temperature for 20 minutes, 16.24 mmoles of  $\alpha,\gamma$ -(tButyl)-L-Aspartic acid and 19.92 mmoles N,N'-diisopropylethylamine were added. After stirring at room temperature for 16 hours, the reaction was worked up by aqueous extraction and ion exchange chromatography.

Purity: single spot on TLC, identity confirmed by MS and NMR. Yield: 99%.

Step 3:

Into a 250 mL round bottom flask was added 0.7 mmoles of compound from Step 2 above, 100 mL DMSO:DMF:THF (1.5:3.5:5, v/v), 27.5 mmoles N-hydroxybenzotriazole, and 27.5 mmoles EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide). After stirring at room temperature for 20 minutes, 55 mmoles of  $\alpha$ -BOC-L-Lysine and 68.7 mmoles N,N'-diisopropylethylamine were added. After stirring at room temperature for 16 hours, the reaction was worked up by aqueous extraction and Gel permeation chromatography.

Purity: single spot on TLC.

Step 4:

Into a 250 mL round bottom flask was added compound from Step 3 above, 40 mL DMF:DCM (2:2, v/v), 23.5 mmoles

- 24 -

N-hydroxybenzotriazole, and 23.5 mmoles EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide). After stirring at room temperature for 30 minutes, 75 mmoles of 2-methoxyethanolamine were added. After stirring at room temperature overnight, the reaction was worked up by aqueous extraction and Ion Exchange chromatography.

Purity: single spot on TLC. Yield: 90%.

(e) N-Cbz-Aspartamide-(( $\alpha,\gamma$ -Aspartyl- $(\alpha,\gamma$ -Aspartyl-Aspartyl( $\alpha,\gamma$ -Lysyl(( $\alpha$ -methoxyethylamide,  $\epsilon$ -TMT)))))) "Asp15Lys16TMT16 Cluster" (Compound V)

Into a 250 mL round bottom flask was added Compound IV, 1.1 molar equivalents of TMT-NCS and 100 mL of 50 mM sodium borate at pH 9.0. After stirring at room temperature for 48 hours, the reaction was worked up by diafiltration (2000 MW cutoff).

Purity: 80% by RP-HPLC.

Example 2: Symmetric aspartic acid cluster

(a) Bis- $(\alpha,\gamma$ -(tButyl)-Aspartyl)succinamide (Compound I)

Synthetic Route A:

Into a 2 Litre round bottom flask was added 20 mmoles succinic acid, 26 mmoles EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), 24 mmoles triethylamine, 12 mmoles TBTU (2-(1-H-benzotriazolyl-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate), and 150 mL THF:DMF (2:1, v/v), then 20 mmoles  $\alpha,\gamma$ -(tButyl)-L-Aspartic acid. This slurry was allowed to react for 4 days at room temperature and then worked up by aqueous extraction.

- 25 -

Purity: single spot on TLC, identity confirmed by MS and NMR. Yield: 23.2%.

Synthetic Route B:

Into a 2 Litre round bottom flask was added 10 mmoles succinic acid, 100 mL THF:DMF (2:1 v/v), 60 mmoles triethylamine and 20 mmoles TBTU (2-(1-H-benzotriazoyl-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate). After 15 minutes of stirring, 22 mmoles  $\alpha,\gamma$ -(tButyl)-L-Aspartic acid were added. This slurry was allowed to react for 21 hours at room temperature and then worked up by aqueous extraction.

Purity: single spot on TLC, identity confirmed by MS and NMR. Yield: 64.7%.

(b) (Bis- $\alpha,\gamma$ -Aspartyl- ( $\alpha,\gamma$ -(tButyl)-Aspartyl))-succinamide (Compound II)

Step 1:

4.6 mmoles of Compound I was stirred into 100 mL of trifluoroacetic acid/dichloromethane (1:1, v/v) at room temperature for 45 minutes. The reaction was evaporated to dryness at 30°C *in vacuo* and then re-evaporated to dryness from each of five consecutive 100 mL volumes of chloroform.

Step 2:


The product from Step 1 was dissolved in 250 mL THF:DMF (1:1, v/v) with 60 mmoles of triethylamine and 40 mmoles of L-aspartic acid-( $\alpha,\gamma$ -(tButyl)ester. To this solution was added 60 mmoles of TBTU. After 16 hours, an additional 20 mmoles of L-aspartic acid-( $\alpha,\gamma$ -(tButyl)ester was added and the reaction continued--

overnight.

Aqueous workup and ion-exchange chromatography yielded a single major spot on TLC which was identified as the desired compound by MS and NMR. Yield: 90%.

Example 3: X-ray contrast agent

(a) Synthesis of iodinated monomer (Compound I):



(b) Compound I may be coupled to any one of the Asp<sub>x</sub> clusters described in Examples 1 and 2 to form an iodinated X-ray contrast agent.